Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has used its March quarter update to underline a period of operational and strategic transition, as the company positions itself for expanded commercialisation of its FebriDx® platform while strengthening leadership oversight to support its next growth phase.
The company reported a series of regulatory, financial and operational milestones during Q3 FY26, headlined by US Food and Drug Administration (FDA) 510(k) clearance with a CLIA waiver for FebriDx®, significantly broadening its addressable market to around 80 million patients annually and enabling deployment across more than 300,000 US healthcare settings.
CEO Doug Ward said the CLIA waiver approval marked a “defining moment” for the company, positioning Lumos to accelerate uptake of its rapid diagnostic technology across the US healthcare system.
“Closing out this quarter with a new 510(k) clearance with attached CLIA waiver for FebriDx® marks a defining moment for Lumos. These achievements are the direct result of the skill, focus and determination our team brings to delivering high-quality, care-changing solutions. I want to extend my sincere thanks to the patients who participated in the clinical studies that supported these approvals, as well as to BARDA for their continued support. I also want to acknowledge our partners who are working closely with us to drive FebriDx® uptake across the US healthcare system. And to our shareholders, thank you for your support through the recent A$20 million placement and in considering the current SPP. Your commitment is critical in positioning Lumos for the growth opportunities ahead.”
Leadership focus aligns with commercial scale-up
Thsi quarter reflects a broader shift in governance priorities towards execution, commercial scaling and partnership delivery. The company’s leadership is increasingly focused on translating regulatory success into sustained revenue growth, particularly in the US market through its agreement with PHASE Scientific.
This strategic emphasis is supported by strengthened financial capacity following a A$20 million placement and incoming milestone payments, providing the balance sheet flexibility required to support manufacturing scale-up, market penetration and ongoing clinical programs.
Milestone payments bolster funding position
During the quarter, Lumos secured multiple milestone payments tied to its FebriDx® program, including US$5 million from PHASE Scientific and US$0.5 million from BARDA following the CLIA waiver approval. A further US$0.72 million was received in relation to progress in its BARDA-funded paediatric study.
These non-dilutive funding streams are aligned with the company’s development roadmap and reflect continued validation from both commercial and government partners.
Revenue growth and capital raise support expansion
Lumos reported quarterly revenue of US$4.8 million, up 37% on the prior corresponding period, split evenly between product and services revenue at US$2.4 million each. Operating cash outflows totalled US$2.8 million, primarily driven by inventory investment to support anticipated demand.
The company ended the quarter with US$1.1 million in cash but has since strengthened its position through the PHASE Scientific milestone payment and proceeds from the placement. A share purchase plan (SPP) is also underway on matching terms, closing 24 April 2026.
Pipeline and partnership delivery remain key priorities
Management continues to prioritise three core areas:
- Driving FebriDx® adoption in the US.
- Advancing the BARDA-backed paediatric study—expected to expand the addressable market by a further 15–20%.
- Progressing development milestones under its Hologic fFN project, which could deliver an additional US$3.4 million in milestone payments.
With regulatory clearance secured, capital raised and partnerships advancing, Lumos’ evolving leadership focus appears firmly centred on execution—turning clinical and regulatory success into commercial scale.
The company invites investors and analysts to attend its Q3 FY26 results webinar, to be held online on Tuesday, April 21, 2026 at 11:00am (AEST.) Participants can register ahead of time, via the following link: https://us02web.zoom.us/webinar/register/WN_LGuVX42cSH6Fq0asH0O5uw